ANNX 250117 4.00P (ANNX250117P4000) Stock Options, News & Quotes

0.20
0.000.00%

15min DelayClose Jan 10 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 16, 2024 06:45

NEWS

$Annexon (ANNX.US)$
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
Annexon (ANNX) announced positive topline results from a real-world evidence study comparing ANX005 treatment to IVIg/PE for Guillain-Barré Syndrome (GBS). The study matched 79 ANX005-treated patients from Phase 3 trials with 79 real-wo...

Trytosaveabit

Dec 16, 2024 06:34

Update

$Annexon (ANNX.US)$ Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
4 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in Interna...

Jaguar8

Oct 21, 2024 19:01

NEWS

$Annexon (ANNX.US)$
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon presented new Phase 2 datafor ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Ke...

Trytosaveabit

Oct 8, 2024 16:47

Time to start watching for data release again! Hehehe!

$Annexon (ANNX.US)$ Looking for this soon.
((((((. ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 )))))

Trytosaveabit

Aug 13, 2024 04:34

Note the dates!

$Annexon (ANNX.US)$ Key Anticipated Milestones for Flagship Programs
*ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025
*ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024